Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
News and updates for Numinus Wellness Inc. (NUMIF) focus on its activities as a mental health care company centered on safe, evidence-based psychedelic-assisted therapies. Company announcements consistently describe efforts to advance behavioral health treatments through clinical trial research, practitioner training and technology-driven support for clinic-based delivery of psychedelic-assisted therapy.
Readers of the Numinus news feed can expect coverage of financial results, including quarterly updates that discuss revenue trends, gross margin, operating expenditures and cash position. These releases often highlight performance at Cedar Clinical Research, where Numinus manages clinical trials and provides research services for drug sponsors, as well as metrics related to its practitioner training business.
Corporate news also includes strategic and organizational developments. Numinus has reported the sale of its U.S. clinic network, the wind-down of non-operating subsidiaries through bankruptcy, and leadership changes such as the appointment of a new Chief Executive Officer and transitions in the Chief Financial Officer role. Additional updates describe accreditation milestones for its Psychedelic-Assisted Therapy Training Program in jurisdictions such as Oregon and Colorado, and engagements like Cedar Clinical Research’s participation in a Phase 3 multinational trial for CYB003 targeting Major Depressive Disorder.
Regulatory and capital markets developments are another recurring theme. Numinus has issued news about a cease trade order affecting its shares, its application to the British Columbia Securities Commission for revocation, and its stated intention to pursue relisting on another reputable exchange once conditions permit. For investors and observers, following NUMIF news provides insight into the company’s operational focus, restructuring steps, regulatory progress and evolving role in the psychedelic-assisted therapy ecosystem.
Numinus Wellness reported fiscal Q1 2022 results, showcasing a robust cash position of $53.9 million and a significant 245% year-over-year revenue growth to $0.8 million. The company achieved a gross profit of $50,965, marking a 6.5% gross margin. Notable operational advancements include a clinical trial application for its proprietary psilocybe extract and the initiation of a MAPS-sponsored MDMA-Assisted Therapy study for PTSD. Numinus continues to expand its wellness clinic network, enhancing its capability to provide psychedelic-assisted psychotherapy services.
Numinus Wellness reported strong financial results for Q4 and FY 2021, with revenues increasing by 81% year-over-year to $0.5 million in Q4 and 72% to $1.5 million for the full year. The company boasts a robust cash position of $59.2 million. Despite a gross profit of $31,818 for Q4, Numinus incurred a quarterly loss of $7.8 million, which included a $1.6 million non-cash impairment charge. Key initiatives include the acquisition of the Neurology Centre of Toronto and the launch of clinical trials for psilocybin and MDMA therapies.
Numinus Wellness Inc. (TSXV: NUMI) will change its OTC Pink market ticker symbol to NUMIF from LKYSF on November 22, 2021, enhancing alignment with its TSX-V listing. The company has also gained DTC Eligibility, allowing its shares to be electronically cleared and settled. This move is seen as a critical first step in expanding its U.S. capital markets strategy, according to CEO Payton Nyquvest. Numinus aims to transform mental health care by integrating psychedelic-assisted therapies into mainstream practice.